Novo Nordisk's next-gen obesity drug Cagrisema: investors seek …
2 days ago · Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...
News Details - novonordisk.com
Dec 20, 2024 · Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).
Investors grow anxious at Novo Nordisk's silence over CagriSema …
1 day ago · Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results BY Ryan Hogg Novo Nordisk is set to release annual results on Wednesday.
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema …
1 day ago · In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without added side effects. A key issue emerging from the trial is that only 57.3% of patients reached the ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual...
Novo Nordisk affirms 25% weight-loss expectation for …
Nov 6, 2024 · Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new...
News Details - Novo Nordisk
Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide.
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
2 days ago · Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...